A rising wave of tumor-agnostic therapies were one of ESMO’s themes, highlighted during the opening press conference by Toni ...

People with multiple sclerosis (MS) have altered levels of several key bacteria in the mouth, a new study reports.

Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024: Revenue: $3.56 billion versus $3.28 billion ...

Disc Medicine is planning to launch a trial by year's end to test DISC-3405, its treatment candidate for iron overload, in ...

Bridgebio Pharma says it will seek U.S. approval of BBP-418 for LGMD2i after Phase 3 trial data showed a range of benefits ...